Literature DB >> 21211937

Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?

Dermot S O'Callaghan1, Peter Dorfmuller, Xavier Jaïs, Luc Mouthon, Olivier Sitbon, Gérald Simonneau, Marc Humbert, David Montani.   

Abstract

Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension that may develop in patients with connective tissue diseases (CTD). Most cases have been reported in patients with systemic sclerosis, though associations with systemic lupus erythematosis and mixed connective tissue disease have also been described. PVOD is characterised by progressive obstruction of small pulmonary veins and venules that leads to increased pulmonary vascular resistance, right heart failure and premature death. Distinguishing PVOD from pulmonary arterial hypertension (PAH) is often difficult, though use of a diagnostic algorithm may improve diagnostic accuracy and preclude recourse to lung biopsy. The finding of normal left-heart filling pressures in the context of radiological studies suggestive of pulmonary oedema is an important diagnostic clue, particularly if this clinical scenario coincides with the introduction of vasodilator therapy. There are no approved treatments for the disorder, though cautious use of PAH specific therapy may improve short-term outcomes in selected idiopathic PVOD cases. This review summarises the epidemiologic, clinico-pathologic and imaging characteristics of PVOD in the setting of CTD and discusses potential management approaches. Copyright Â
© 2010. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Year:  2011        PMID: 21211937     DOI: 10.1016/j.lpm.2010.10.017

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  6 in total

Review 1.  An update on the evaluation and management of pulmonary hypertension in scleroderma.

Authors:  John G Coghlan; Benjamin Schreiber; Benjamin Schrieber
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 2.  Rare causes of pulmonary hypertension: spectrum of radiological findings and review of the literature.

Authors:  Alice Rossi; Maurizio Zompatori; Patrick Tchouante Tchouanhou; Michele Amadori; Massimiliano Palazzini; Elisa Conficoni; Nazzareno Galiè; Venerino Poletti; Giampaolo Gavelli
Journal:  Radiol Med       Date:  2013-11-15       Impact factor: 3.469

Review 3.  Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis.

Authors:  Aaliya Yaqub; Lorinda Chung
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

4.  Sex differences in response to tadalafil in pulmonary arterial hypertension.

Authors:  Stephen C Mathai; Paul M Hassoun; Milo A Puhan; Yi Zhou; Robert A Wise
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

5.  Pulmonary veno-occlusive disease: the role of CT.

Authors:  Giangaspare Mineo; Domenico Attinà; Martina Mughetti; Caterina Balacchi; Fiorella De Luca; Fabio Niro; Federica Ciccarese; Luigi Lovato; Vincenzo Russo; Francesco Buia; Cecilia Modolon; Alessandra Manes; Massimiliano Palazzini; Nazareno Galiè; Maurizio Zompatori
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

Review 6.  Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Authors:  Marc Humbert; Manjit Singh; Daniel E Furst; Dinesh Khanna; James R Seibold
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.